Expertise
Dr. Chism brings together clinical oncology experience, research leadership, medical education, and an informed understanding of how multidisciplinary cancer programs operate. He offers experienced clinical and strategic insight to healthcare organizations, professional associations, research groups, and life sciences companies.
Dr. Chism’s clinical experience spans hematology and medical oncology, with particular depth in genitourinary cancers, systemic cancer therapies, and multidisciplinary care.
At Vanderbilt-Ingram Cancer Center, he coordinated care across medical oncology, radiation oncology, urologic oncology, pathology, radiology, and supportive care. His work reflects a commitment to collaboration, informed decision-making, and coordinated patient care.
Through clinical and academic roles at Tennessee Oncology, Thompson Cancer Survival Center, Vanderbilt University Medical Center, and Wesley Long Cancer Center, Dr. Chism has developed a broad understanding of oncology practice across varied care environments. This experience informs his perspective on clinical strategy, medical education, physician leadership, and the delivery of high-quality cancer care.
As Medical Director of Clinical Research, Dr. Chism led the design, implementation, and evaluation of investigator-initiated and industry-sponsored studies across multiple disease sites.
His experience includes clinical trial strategy, correlative science, patient safety, research quality, regulatory and ethical compliance, and operational performance. His national leadership has also included work focused on oncology workforce sustainability, quality improvement, and high-value cancer care.
As a published investigator, Dr. Chism has contributed to research spanning genitourinary oncology, immunotherapy, emerging systemic treatments, cancer disparities, cardio-oncology, and the effects of COVID-19 on patients with cancer. His work includes participation in collaborative studies and clinical trials examining both treatment advances and the broader factors affecting patient outcomes.
His service through national oncology committees has further informed his understanding of access to clinical trials, research standards, workforce challenges, and care delivery across the United States. This combination of research leadership and clinical experience enables him to consider not only how new treatments are studied, but how advances can be translated into safe, effective, and accessible patient care.
Dr. Chism brings a practicing physician’s perspective to advisory discussions involving oncology, research, medical affairs, healthcare leadership, and clinical strategy.
Consultantships
June 2023
Consultant, Astrazeneca, Virtual Board, Breast Cancer National Advisory Board Meeting
June 2023
Consultant, Regeneron, New York, New York, Lung Cancer National Advisory Board Meeting
April 2018
Consultant, Pfizer, Virtual Board, Kidney Cancer National Advisory Board Meeting
June 2017
Consultant, Karyopharm Inc., Chicago, Illinois, Oncology Medical Affairs: Prostate Cancer National Advisory Board Meeting
December 2016
Consultant, Exelixis, Chicago, Illinois, Kidney Cancer National Advisory Board Meeting
